SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 /PRNewswire/ Rigel Pharmaceuticals, Inc. today announced that it will report its fourth quarter and full year 2023 financial results after market.
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has entered into a definitive agreement to acquire the U.S. rights.
Rigel Pharma (RIGL) Acquires U S Rights to GAVRETO from Blueprint Medicines (BPMC) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.